News | August 28, 2024
Royal Sense launches multiple products in pharmaceutical category
Launches Opentop 40, Opentop D, Opentop L, Opentop Dsr and Cefix 200 which are available for sale
Launches Opentop 40, Opentop D, Opentop L, Opentop Dsr and Cefix 200 which are available for sale
Capital expenditure expected to moderate to Rs. 5.6 billion in FY2025 from an estimated Rs. 7.6 billion in FY2024
Q1FY25 Revenue from Operations grew by 15% to Rs. 177 crore
This strong performance was primarily on account of a one-time gain from the strategic collaboration between Biocon Biologics and Eris Lifesciences.
The EIR was issued post the last inspection of the facility conducted from May 6-10, 2024 which concluded with zero FDA 483 observations
The drugmaker's net profit slipped 26 per cent on-year to Rs 143.8 crore
Revolutionary technology will further boost OneSource’s scientific services offerings
BAV has revolutionized the animal vaccination industry with its ground-breaking delivery methods that prioritize quality, safety, and efficacy
The partnership will focus on creating capabilities for quickly and accurately processing vast amounts of clinical data
dsm-firmenich decided to de-prioritize certain business segments, including the MEG-3 business
Subscribe To Our Newsletter & Stay Updated
